Germany’s EVANIUM Raises €2.2M for Nutraceutical Innovation

Key Takeaways

1. Regensburg based EVANIUM has raised €2.2M in seed funding to scale its IP protected OPTISOLV drug delivery technology for nutraceutical ingredients.
2. The round is backed by FoodLabs and Feast Ventures, alongside existing angel investors, to support team expansion, clinical studies, and commercial partnerships.
3. EVANIUM’s platform improves solubility and bioavailability of plant based compounds for supplements, functional foods, and nutricosmetics, targeting what it calls a “bioavailability crisis” in the sector.
4. The company already works with partners such as Hevert Arzneimittel and is rolling out an ingredient portfolio including Optisolv Curcumin and Optisolv Berberine.

Quick Recap

Germany’s EVANIUM, a Regensburg based life science startup, has secured a €2.2M seed round to advance its OPTISOLV drug delivery technology for nutraceutical applications. The funding, announced via EU Startups on X and confirmed in specialist nutrition media, will help the company scale production, expand its team, and accelerate commercial partnerships across supplements, functional foods, and nutricosmetics. Positioned as a response to poor bioavailability in many plant based ingredients, the round marks a notable early stage bet on next generation nutraceutical formulations.

Scaling Nutraceutical Delivery Innovation

EVANIUM’s core asset is OPTISOLV, an IP protected drug delivery technology designed to enhance the water solubility, stability, and absorption of poorly soluble plant based compounds such as polyphenols and flavonoids. By using a dual coating system, OPTISOLV aims to significantly improve bioavailability and taste, enabling brands to formulate lower dose yet more effective nutraceutical and functional food products.

The €2.2M seed capital will be deployed to scale manufacturing of OPTISOLV ingredients, accelerate clinical validation, and grow commercial pipelines in nutraceuticals, nutricosmetics, functional foods, and pharma adjacent use cases. Investors FoodLabs and Feast Ventures, together with existing angels, are positioning EVANIUM as an ingredient platform rather than a consumer brand, allowing it to plug into established supplement and OTC portfolios.

The company’s existing product line includes Optisolv Curcumin, launched with German herbal medicine manufacturer Hevert Arzneimittel, and ingredients such as Optisolv Berberine, Boswellia, and Passiflora. These ingredients are designed to tackle use cases from metabolic health to inflammation support, with Optisolv Berberine recognized as a finalist in the Vitafoods Europe 2026 Start Up Challenge for “Most Innovative Nutraceutical Ingredient.” 

Why EVANIUM matters in the nutraceutical race?

EVANIUM’s raise comes at a time when supplement brands are under pressure to demonstrate efficacy rather than rely on high dosage labels and generic commodity extracts. Many botanical compounds suffer from poor water solubility and low bioavailability, meaning consumers often do not receive the expected physiological benefit despite high on pack milligram counts.

By focusing on enabling technologies that improve delivery rather than just new ingredients, EVANIUM taps into a broader trend toward “formulation first” innovation in nutraceuticals and functional foods. The market for advanced delivery systems in nutraceuticals is also being shaped by regulatory and retailer scrutiny, particularly in Europe, where efficacy claims and dosing are increasingly examined by authorities and informed consumers.

Ingredient platforms like EVANIUM that can demonstrate improved absorption through data and clinical work are likely to be attractive partners for mid sized supplement brands that lack deep internal R&D. With Optisolv Berberine gaining visibility at Vitafoods Europe 2026, the company is positioning itself not only as a formulation technology provider but also as a branded ingredient player in competitive health categories such as metabolic support.

Competitive landscape

While EVANIUM operates in nutraceutical ingredients rather than AI, the following table mirrors a feature style comparison to help readers quickly parse positioning versus similar scale peers focused on bioavailability technologies. As relevant peers, we highlight Aquanova (NovaSol) and Bioiberica’s branded ingredient portfolio, both active in enhanced delivery or high value nutraceutical ingredients.

In a feature style reading of this landscape, EVANIUM scores strongest on specialization in plant based actives and on branded seed stage innovation, while Aquanova and Bioiberica still dominate in global scale and established distribution. For brands seeking differentiated, next generation plant ingredient formats, EVANIUM looks competitive, but for immediate global rollout, incumbent suppliers retain an advantage.

TechnoTrenz’s Takeaway

In my experience, seed rounds of this size in specialized ingredient tech can be pivotal, because they often determine whether a platform like OPTISOLV matures into a category standard or remains a niche formulation tool.

I think this is a big deal because EVANIUM is targeting the structural bioavailability problem that frustrates both brands and consumers, rather than just adding another high dose botanical to an already crowded shelf. From a financing perspective, backing from focused food and biotech investors signals a reasonably bullish view on nutraceutical innovation that leans on data and formulation science.

I generally prefer models where the startup remains ingredient and platform focused while letting established brands handle marketing, and EVANIUM appears to be following exactly that path. For readers and industry operators, I would frame this as a constructive, moderately bullish signal for evidence based nutraceuticals, with real upside if the company can turn its early partnerships and clinical work into repeatable, scalable licensing deals.